secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001213900-23-074164
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Therapeutics appoints veteran drug developer Sara Kenkare-Mitra to board
--------------------------------------------------------------------------------

- Appointed Sara Kenkare-Mitra, PhD as independent director effective September 6, 2023.
- Dr. Kenkare-Mitra is President & Head of R&D at Alector; previously 23 years at Genentech as SVP.
- She played key role in >100 IND/CTA filings and 11 drug approvals across multiple diseases.
- Her expertise expected to help advance oxylanthanum carbonate toward NDA filing and UNI-494 IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023074164/0001213900-23-074164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023074164/ea184727-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-074164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer